Aevi Genomic Medicine (Aevi Genomic Medicine) Total Assets : $2.80 Mil (As of Sep. 2019)

View and export this data going back to 2007. Start your Free Trial

What is Aevi Genomic Medicine Total Assets?

Aevi Genomic Medicine's Total Assets for the quarter that ended in Sep. 2019 was $2.80 Mil.

Total Assets is connected with ROA %. Aevi Genomic Medicine's annualized ROA % for the quarter that ended in Sep. 2019 was -474.34%. Total Assets is also linked to Revenue through Asset Turnover. Aevi Genomic Medicine's Asset Turnover for the quarter that ended in Sep. 2019 was 0.00.

Aevi Genomic Medicine Total Assets Historical Data

The historical data trend for Aevi Genomic Medicine's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aevi Genomic Medicine Total Assets Chart

Aevi Genomic Medicine Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Total Assets

Get a 7-Day Free Trial

34.28

54.26

40.56

34.76

12.28

Aevi Genomic Medicine Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Total Assets	Get a 7-Day Free Trial															20.19	12.28	7.62	4.02	2.80

Aevi Genomic Medicine Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Aevi Genomic Medicine's Total Assets for the fiscal year that ended in Dec. 2018 is calculated as

Total Assets	=	Total Equity (A: Dec. 2018 )	+	Total Liabilities (A: Dec. 2018 )
	=	7.932	+	4.345
	=	12.28

Aevi Genomic Medicine's Total Assets for the quarter that ended in Sep. 2019 is calculated as

Total Assets	=	Total Equity (Q: Sep. 2019 )	+	Total Liabilities (Q: Sep. 2019 )
	=	-3.457	+	6.253
	=	2.80

Aevi Genomic Medicine (NAS:GNMX) Total Assets Explanation

Total Assets is connected with ROA %.

Aevi Genomic Medicine's annualized ROA % for the quarter that ended in Sep. 2019 is

ROA %	=	Net Income (Q: Sep. 2019 )	/	( (Total Assets (Q: Jun. 2019 )	+	Total Assets (Q: Sep. 2019 ))	/ count )
	=	-16.168	/	( (4.021	+	2.796)	/ 2 )
	=	-16.168	/	3.4085
	=	-474.34 %

Note: The Net Income data used here is four times the quarterly (Sep. 2019) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Aevi Genomic Medicine's Asset Turnover for the quarter that ended in Sep. 2019 is

	Asset Turnover
=	Revenue (Q: Sep. 2019 )	/	( (Total Assets (Q: Jun. 2019 )	+	Total Assets (Q: Sep. 2019 ))	/ count )
=	0	/	( (4.021	+	2.796)	/ 2 )
=	0	/	3.4085
=	0.00

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Aevi Genomic Medicine Total Assets Related Terms

Thank you for viewing the detailed overview of Aevi Genomic Medicine's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Aevi Genomic Medicine (Aevi Genomic Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aevi Genomic Medicine Inc (NAS:GNMX) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

435 Devon Park Drive, Suite 715, Wayne, PA, USA, 19087

Website

http://www.aevigenomics.com

Medgenics is a clinical-stage biopharmaceutical company involved mainly in genomic medicine. Genomic medicine involves the usage of individual's genomic information to decide upon clinical care. This medical discipline is used in the fields of oncology, pharmacology, rare and undiagnosed diseases, and infectious diseases. Medgenics' partner is the Center for Applied Genomics at the Children's Hospital of Philadelphia, with which it works to develop drugs by implementing genomics medicine.

Executives

Michael F Cola	director, officer: Chief Executive Officer	435 DEVON PARK BUILDING 800, WAYNE PA 19087-1945
Sol J Barer	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Barbara Gayle Duncan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES STREET, NEW YORK NY 10013
Garry Arthur Neil	officer: Chief Scientific Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Eugene A Bauer	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Alastair J Clemow	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
Grano Joseph J Jr	director	C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Plc Astrazeneca	10 percent owner	1 FRANCIS CRICK AVENUE, CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0 CB2 0AA
Brian Piper	officer: CFO & Corporate Secretary	C/O MEDGENICS, INC., 435 DEVON PARK DRIVE, BLDG. 700, WAYNE PA 19087
Wilbur H Gantz	director	C/O MEDGENICS, INC., 435 DEVON PARK DRIVE BLDG 700, WAYNE PA 19087
Scott Applebaum	officer: Chief Legal Officer	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Isaac Blech	director	C/O INSPIREMD, INC., 321 COLUMBUS AVENUE, BOSTON MA 02116
Joel S Kanter	director	C/O APPLIED UV, INC., 150 N. MACQUESTEN PKWY, MOUNT VERNON NY 10550
John Harold Leaman	officer: Chief Financial Officer	555 CALIFORNIA STREET, SUITE 365, SAN FRANCISCO CA 94104
Clarence L Dellio	officer: Chief Operating Officer	435 DEVON PARK DRIVE BLDG 700, C/O MEDGENICS, INC., WAYNE PA 19087